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The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of CAC chemokine receptor types 2 and 5,
for treatment of nonalcoholic steatohepatitis (NASH) with liver ﬁbrosis (LF). A randomized, double-blind, multinational
phase 2b study enrolled subjects with NASH, a nonalcoholic fatty liver disease activity score (NAS) 4, and LF (stages 1-
3, NASH Clinical Research Network) at 81 clinical sites. Subjects (N 5 289) were randomly assigned CVC 150 mg or
placebo. Primary outcome was 2-point improvement in NAS and no worsening of ﬁbrosis at year 1. Key secondary out-
comes were: resolution of steatohepatitis (SH) and no worsening of ﬁbrosis; improvement in ﬁbrosis by 1 stage and no
worsening of SH. Biomarkers of inﬂammation and adverse events were assessed. Full study recruitment was achieved. The
primary endpoint of NAS improvement in the intent-to-treat population and resolution of SH was achieved in a similar
proportion of subjects on CVC (N 5 145) and placebo (N 5 144; 16% vs. 19%, P 5 0.52 and 8% vs. 6%, P 5 0.49,
respectively). However, the ﬁbrosis endpoint was met in signiﬁcantly more subjects on CVC than placebo (20% vs. 10%; P
5 0.02). Treatment beneﬁts were greater in those with higher disease activity and ﬁbrosis stage at baseline. Biomarkers of
systemic inﬂammation were reduced with CVC. Safety and tolerability of CVC were comparable to placebo. Conclusion:
After 1 year of CVC treatment, twice as many subjects achieved improvement in ﬁbrosis and no worsening of SH com-
pared with placebo. Given the urgent need to develop antiﬁbrotic therapies in NASH, these ﬁndings warrant phase 3 eval-
uation. (HEPATOLOGY 2018;67:1754-1767).
Nonalcoholic fatty liver disease (NAFLD) isnow the most common cause of liver disease,with a prevalence of 25% globally.(1) Nonal-
coholic steatohepatitis (NASH), the more severe form
of the disease, is characterized by the presence of stea-
tosis, lobular and/or portal inﬂammation, hepatocyte
injury (i.e., ballooning), and ﬁbrosis.(2) The presence of
liver ﬁbrosis (LF) confers an increased risk of disease
progression to cirrhosis, liver failure, and hepatocellular
carcinoma, with a higher mortality.(3,4) Fibrosis stage
is the only histological feature of NASH independently
linked to an increased likelihood of liver-related and
all-cause (e.g., cardiovascular disease [CVD]) mortality
in recent studies.(3-5) Therefore, reducing LF is
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expected to improve the long-term clinical outcomes
of patients with NASH.(6) Among pharmacological
treatments currently undergoing evaluation, a number
have reported improvement in histological features of
NASH,(6-9) but only obeticholic acid signiﬁcantly
improved ﬁbrosis in a randomized clinical study in
adults with noncirrhotic NASH.(10)
Cenicriviroc (CVC) is an oral, dual antagonist of C-
C motif chemokine receptor (CCR) types 2 and 5.
Preclinical(11-14) and clinical evidence(15-17) support its
anti-inﬂammatory and antiﬁbrotic properties, which are
mediated by CCR types 2 and 5 (CCR2/CCR5) block-
ade. CVC has demonstrated antiﬁbrotic activity in ani-
mal models of LF and renal ﬁbrosis.(11) These ﬁndings
are supported in patients by improvements in noninva-
sive markers of hepatic ﬁbrosis (HF; aspartate
aminotransferase-to-platelet ratio index [APRI],
ﬁbrosis-4 [FIB-4], and enhanced liver ﬁbrosis [ELF]
test) observed in post-hoc analyses of a 48-week phase 2b
study in human immunodeﬁciency virus (HIV)-infected
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subjects.(18,19) Furthermore, extensive clinical experi-
ence using CVC, with over 1,000 subjects treated to
date, indicates a favorable safety proﬁle including in
subjects with cirrhosis and mild-to-moderate (Child-
Pugh A or B) hepatic impairment.(17,20)
CVC-mediated antagonism of CCR2 is expected to
reduce the recruitment, migration, and inﬁltration of
proinﬂammatory monocytes and macrophages at the
site of liver injury.(14,15) CCR5 antagonism by CVC is
expected to additionally impair the migration, activa-
tion, and proliferation of collagen-producing activated
hepatic stellate cells/myoﬁbroblasts.(21) We designed
the phase 2 CENTAUR study to test the efﬁcacy and
safety of CVC in adults with NASH and LF; results
from the year 1 primary analysis are reported here.
Materials and Methods
STUDY DESIGN
The study design, rationale, and procedures of CEN-
TAUR (NCT02217475) have been reported previ-
ously.(15) This is a phase 2b, randomized, double-
blinded, placebo-controlled, and multinational study.
The protocol was approved by the Institutional Review
Board or Independent Ethics Committee for each cen-
ter. The study is being conducted in accord with the
Declaration of Helsinki and with all applicable laws/reg-
ulations of the study locations; all subjects gave written
informed consent. Data were analyzed by Medpace,
Inc., and the sponsor. Authors had access to the data
and participated in drafting the manuscript; editorial
support was funded by the sponsor and provided by
independent medical writers under author guidance. All
authors approved the manuscript and assume full
responsibility for data accuracy and completeness.
Subjects were randomized to receive CVC 150 mg or
a matched placebo once-daily. After 1 year, half of the
subjects receiving placebo crossed over to CVC, based on
preplanned randomization, for a second year of treat-
ment. At baseline, eligible subjects were assigned to the
treatment arms using permuted block randomization
stratiﬁed by NAFLD activity score (NAS) at screening
(4 or 5) and ﬁbrosis stage (2 or >2). Subjects were
randomized 2:1:1 to arm A (CVC 150 mg once-daily for
2 years), arm B (placebo for 1 year then CVC 150 mg for
1 year), or arm C (placebo for 2 years). Randomization
was accomplished by interactive voice response system.
Subjects, the sponsor, investigators, and all site per-
sonnel involved with dispensing study medication, carry-
ing out study procedures, evaluating subjects, entering
study data, and/or evaluating study data remain blinded
to individual treatment assignment until all subjects com-
plete the 2-year study and the database is locked for all
study data. CVC and matching placebo provided by the
sponsor were visually indistinguishable and the packaging
identical except for a unique bottle identiﬁcation number.
We report herein the results at year 1 of treatment, com-
paring CVC to placebo.
Adult subjects with histological evidence of NASH,
a NAS 4 with 1 in each component, and LF
(NASH Clinical Research Network [CRN] stages 1-
3) were enrolled at 81 clinical sites in Australia, Bel-
gium, France, Germany, Hong Kong, Italy, Poland,
Spain, the UK, and the United States. Subjects had
either type 2 diabetes mellitus (T2DM), a high body
mass index (BMI; >25 kg/m2) with 1 criteria of
metabolic syndrome (MetS; National Cholesterol
Education Program’s Adult Treatment Panel III
(ATP III) deﬁnition), or bridging ﬁbrosis (NASH
CRN stage 3) and/or high disease activity (NAS 5).
The screening and year 1 liver biopsies were read by a
central pathologist, who remained blinded to individ-
ual subject treatment assignment. Screening biopsies
were not reread at the time year 1 biopsies were
assessed; however, biopsy sequence was not blinded,
because of logistical challenges.
The study protocol instructed sites to provide and
review patient education materials about NASH and
LF by the National Institute of Diabetes and Digestive
Kidney Diseases at the screening visit, but relied on
local standard of care for implementing diet and life-
style intervention in randomized subjects. Subjects
were excluded from the study if they had bariatric sur-
gery in the past 5 years, or planned bariatric surgery
during the trial. Alcohol consumption (current drinker,
former drinker, or never consumed) was recorded at
baseline and at subsequent visits. Height of subjects
was recorded at screening and month 12; body weight
was monitored at regular intervals (screening, baseline,
and at months 3, 6, and 12 during treatment period 1
[i.e., year 1]). Change in BMI was calculated for CVC
and placebo recipients.
Treatment of T2DM and dyslipidemia was allowed
with certain restrictions or precautions, depending on the
coadministered drug and its drug-drug interaction poten-
tial with CVC. The use of frequently administered con-
comitant medications, including biguanides, glucose-
lowering drugs (excluding insulin), hydroxymethylglutaryl
CoA reductase inhibitors, and angiotensin II inhibitors,
were noted throughout year 1 of the study and are listed
in Supporting Table S1. Pioglitazone and high-dose
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vitamin E (>400 UI/day) were disallowed because of
potential confounding effects on efﬁcacy.
STUDY OUTCOMES
The primary outcome evaluated hepatic histological
improvement at year 1 relative to the screening biopsy
(deﬁned by 2-point improvement in NAS with
1-point reduction in either lobular inﬂammation or
hepatocellular ballooning) and no worsening of ﬁbrosis
stage (i.e., no progression of NASH CRN ﬁbrosis
stage). This endpoint was based on previously pub-
lished phase 2b trials in NASH.(9,10) Two key second-
ary outcomes were prospectively selected based on
regulatory guidance and were evaluated at year 1: (1)
complete resolution of steatohepatitis (SH; histopatho-
logical interpretation of fatty liver disease, or simple or
isolated steatosis and no SH) and no worsening of
ﬁbrosis stage; (2) improvement in ﬁbrosis by 1 stage
(NASH CRN system) and no worsening of SH (no
worsening of lobular inﬂammation or hepatocellular
ballooning grade).
Other secondary outcomes included: change in
ﬁbrosis stage (NASH CRN and Ishak systems);
change in histological scores for steatosis, lobular
inﬂammation, and hepatocellular ballooning; change
in collagen morphometry on liver biopsy; safety and
tolerability of CVC; and change in liver biochemistry
and fasting metabolic parameters. Inﬂammatory bio-
markers were also assessed.
A tertiary objective of the study was to evaluate the
change from baseline in liver stiffness through nonin-
vasive methods (e.g., ultrasound transient elastography,
two-dimensional magnetic resonance elastography, or
acoustic radiation force impulse). Unfortunately, most
sites did not have access to these methods at the time
of initiation of the study; therefore, only a limited
number of subjects had available data.
The Supporting Appendix provides details on
CENTAUR study objectives (Supporting Table S2)
and efﬁcacy endpoints (Supporting Fig. S1).
STATISTICAL ANALYSES
To assess CVC efﬁcacy for the primary endpoint,
the original required sample size was 252 subjects,
assuming a 20% response rate for placebo and a 36%
response rate for CVC at year 1. The study overen-
rolled by 15% but, because of an anticipated dropout
rate of 15%, this sample size was still expected to pro-
vide at least an 80% power to demonstrate superiority
(for a two-sided type 1 error rate of 0.05) of CVC ver-
sus placebo.
The primary efﬁcacy endpoint was analyzed using
logistic regression, which included terms for treatment
and the two stratiﬁcation variables (i.e., baseline NAS
of 4 or 5 and ﬁbrosis stage 2 or >2). A preordered,
step-down approach was used (Supporting Fig. S2). If
statistical signiﬁcance was achieved at a 5 0.05, two-
sided for the primary endpoint, a composite analysis
on the sum of the two key secondary endpoints was to
be performed with an ordinal logistic regression model.
If statistical signiﬁcance was achieved for the summa-
tion, a parallel, simultaneous analysis for each key sec-
ondary endpoint was to be performed. The type I error
rate was controlled for the key secondary endpoints by
only testing the composite analysis if the primary end-
point was positive, and only testing each secondary
endpoint if the composite analysis was also positive.
Supportive analyses were planned in the modiﬁed
intent-to-treat (ITT) population, consisting of all sub-
jects in the ITT population with evaluable biopsies,
and with the full analysis set, compiling all subjects
with evaluable biopsies at both baseline and year 1.
A post-hoc analysis of various factors that might
affect response (including baseline characteristics,
demographics, laboratory tests, and histological fea-
tures) was conducted without control of the type I
error rate. In a logistic regression model, potential pre-
dictors were added to the model in a step-wise selec-
tion process if the P value was less than or equal to
0.30 after adjustment for all previously included fac-
tors. When all such factors were found, those with
resulting P values less than or equal to 0.05 were con-
sidered nominally signiﬁcant after adjustment for all
other potential predictors.
Results
SUBJECTS
This phase 2b, randomized, double-blinded, pla-
cebo-controlled, multinational study was initiated in
September 2014 and fully enrolled by June 2015. It is
currently ongoing and will be conducted over 2 years,
with the primary analysis having been performed at
year 1 (cut-off date July 2016). A total of 812 subjects
were screened; 610 underwent liver biopsy and 289
were randomized to treatment (Fig. 1). At the end of
year 1, 252 subjects had available screening and year 1
biopsies. The primary efﬁcacy analysis, reported in the
ITT population, comprised all randomized subjects.
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Baseline demographics and disease characteristics
are presented in Table 1. With the exception of
T2DM, the treatment groups were well balanced.
Overall, 51% (146 of 289) of subjects had T2DM,
95% (273 of 289) had BMI >25 kg/m2 with 1 cri-
teria of MetS, and 38% (111 of 289) had bridging
ﬁbrosis (NASH CRN stage 3). A total of 72% (208
of 289) of subjects met 3 criteria of MetS. The
majority of subjects had NAS 5 (74% [214 of 289])
and 67% (193 of 289) had ﬁbrosis stage 2 or 3 at
screening.
PRIMARY AND KEY SECONDARY
OUTCOMES
At year 1, a similar proportion of subjects receiving
CVC or placebo achieved the primary endpoint of
hepatic histological improvement in NAS by 2
points and no worsening of ﬁbrosis stage (16% vs.
19%; odds ratio [OR], 0.82 [95% conﬁdence interval
fCIg, 0.44-1.52]; P 5 0.52; Fig. 2A).
Analysis of the key secondary endpoints was con-
ducted as prespeciﬁed and is presented for full
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FIG. 1. Subject disposition (CONSORT ﬂow diagram). aThe disposition of 4 subjects who withdrew early (1 for protocol deviation,
1 lost to follow-up, 1 because of physician’s decision, 1 other) cannot be reported in speciﬁc treatment arm as the study is ongoing
and remains blinded. bLiver biopsy sample too small or fragmented, therefore inadequate for assessment of efﬁcacy endpoints. cA sub-
ject was randomized in error without an adequate screening biopsy. Abbreviation: CONSORT, Consolidated Standards of Reporting
Trials.
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disclosure of data, although the primary endpoint
was not met. The composite secondary endpoint
(summation of “complete resolution of SH and no
worsening of ﬁbrosis stage” and “improvement in
ﬁbrosis stage by 1 stage and no worsening of
SH”) was achieved by signiﬁcantly more subjects
receiving CVC than those receiving placebo (18%
vs. 10%; OR, 1.93 [95% CI, 1.04-3.61]; P 5 0.04).
When the two key secondary endpoints were ana-
lyzed separately, a similar proportion of subjects
achieved complete resolution of SH and no worsen-
ing of ﬁbrosis stage (8% vs. 6%; OR, 1.40 [95% CI,
0.54-3.63]; P 5 0.49), whereas twice as many sub-
jects on CVC achieved improvement in ﬁbrosis
stage by 1 stage and no worsening of SH com-
pared to those on placebo (20% vs. 10%; OR, 2.20
[95% CI, 1.11-4.35]; P 5 0.02; Fig. 2B).
SUBGROUP ANALYSES FOR KEY
SECONDARY FIBROSIS
ENDPOINT
CVC provided antiﬁbrotic beneﬁts in both ﬁbrosis
strata (stages2 and>2; Figs. 2C and 3). When subjects
TABLE 1. Baseline Demographics and Disease Characteristics of Randomized Subjects per Treatment Group
CVC 150 mg
(N 5 145)
Placebo
(N 5 144)
All
(N 5 289)*
Demographics
Mean age, year (SD) 54.6 (10.2) 53.7 (11.0) 54.1 (10.6)
Female, no. (%) 73 (50.3) 79 (54.9) 152 (52.6)
Race or ethnicity, no. (%)
White 129 (89.0) 121 (84.0) 250 (86.5)
Black 5 (3.4) 3 (2.1) 8 (2.8)
Asian 6 (4.1) 15 (10.4) 21 (7.3)
Hispanic ethnicity 23 (15.9) 25 (17.4) 48 (16.6)
Serum biochemistry
Mean alanine aminotransferase, U/L (SD) 61.3 (35.2) 65.5 (39.6) 63.4 (37.5)
Mean aspartate aminotransferase, U/L (SD) 43.7 (22.0) 48.3 (24.0) 46.0 (23.1)
Mean alkaline phosphatase, U/L (SD) 79.0 (20.9) 80.8 (27.8) 79.9 (24.5)
Mean gamma-glutamyl transferase, U/L (SD) 69.6 (79.0) 65.2 (43.5) 67.4 (63.7)
Mean total bilirubin, mg/dL (SD) 0.510 (0.531) 0.483 (0.273) 0.496 (0.422)
Lipids
Triglycerides
Mean, mg/dL (SD) 180.3 (149.0) 174.5 (110.1) 177.4 (130.8)
>150 mg/dL, no. (%) 70 (48.3) 71 (49.3) 141 (48.8)
Mean cholesterol, mg/dL (SD)
Total 192.5 (48.9) 187.9 (47.4) 190.2 (48.1)
High-density lipoprotein 42.1 (12.2) 40.9 (13.2) 41.5 (12.7)
Low-density lipoprotein 121.9 (44.4) 118.7 (42.8) 120.3 (43.6)
Very-low-density lipoprotein 36.1 (30.0) 34.9 (22.0) 35.5 (26.3)
Metabolic factors
Mean body weight, kg (SD) 95.1 (20.4) 97.1 (21.9) 96.1 (21.1)
Mean BMI, kg/m2 (SD) 33.6 (5.7) 34.1 (7.2) 33.9 (6.5)
Mean HbA1c, % (SD) 6.71 (1.36) 6.37 (1.15) 6.54 (1.27)
T2DM, no. (%) 82 (57.2) 64 (44.4) 146 (50.5)
3 criteria of MetS, no. (%) 104 (71.7) 104 (72.2) 208 (72.0)
Histological features
NAFLD activity score
Mean total (SD) 5.3 (1.1) 5.4 (1.0) 5.3 (1.0)
Mean steatosis (SD) 1.4 (0.6) 1.4 (0.5) 1.4 (0.6)
Mean lobular inflammation (SD) 2.4 (0.6) 2.4 (0.6) 2.4 (0.6)
Mean hepatocellular ballooning (SD) 1.5 (0.5) 1.5 (0.5) 1.5 (0.5)
NAS
5 4, no. (%) 39 (26.9) 35 (24.3) 74 (25.6)
5, no. (%) 106 (73.1) 108 (75.0) 214 (74.0)
Fibrosis stage (NASH CRN)
1, no. (%) 47 (32.4) 48 (33.3) 95 (32.9)
2, no. (%) 42 (29.0) 40 (27.8) 82 (28.4)
3, no. (%) 56 (38.6) 55 (38.2) 111 (38.4)
*One subject was randomized in error without an adequate screening biopsy.
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with baseline ﬁbrosis stages 2 and 3 were pooled, CVC
beneﬁts were signiﬁcant (P < 0.05; Figs. 2D and 3).
CVC treatment beneﬁts were consistent across prespeci-
ﬁed subgroups; the greatest treatment beneﬁts were in
subjects with baseline NAS5 and those with prominent
hepatocellular ballooning, relative to those with baseline
NAS54 and few ballooned cells (Figs. 2E,F and 3).
A post-hoc analysis was conducted to evaluate the
effect of biopsy length (<15 or 15 mm), in the modi-
ﬁed ITT population (Supporting Table S3). The
majority of liver biopsies collected at baseline (78%-
83%) and year 1 (79%-82%) had a length of 15 mm,
a length above which sampling variability is expected
to be lower.
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FIG. 2. Primary endpoint and
key secondary endpoint of
improvement in ﬁbrosis by 1
stage and no worsening of SH at
year 1 (ITT analysis), with sub-
group analyses for the key second-
ary endpoint (mITT population).
(A) Subjects meeting the primary
endpoint (improvement in NAS
and no worsening of ﬁbrosis). (B)
Subjects meeting the key second-
ary endpoint of improvement in
ﬁbrosis by 1 stage and no wors-
ening of SH. Missing biopsies
were counted as treatment failure.
(C,D,E,F) Response for the key
secondary endpoint by baseline:
(C) ﬁbrosis stage (NASH CRN
system); (D) ﬁbrosis stages 2 and 3
pooled (NASH CRN system); (E)
NAS stratiﬁcation; and (F) hepa-
tocellular ballooning grade. OR are
presented with 95% CI and P val-
ues and were calculated using a
logistic regression model with fac-
tors for randomized treatment
group, NAS at screening (4 or
5), and ﬁbrosis stage (2 or
>2). Abbreviation: mITT, modi-
ﬁed intent-to-treat.
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Findings from this post-hoc analysis were generally
consistent with the main results, except for the smaller
subset of subjects with a year 1 liver biopsy length of
<15 mm, where placebo response was higher than in
other placebo subgroups (22%; 6 of 27 placebo-treated
subjects). In contrast, the most pronounced treatment
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FIG. 3. Subgroup analyses for
the key secondary endpoint of
improvement in ﬁbrosis by 1
stage and no worsening of SH
(mITT population). Response
by baseline NAS stratiﬁcation,
ﬁbrosis stage (NASH CRN
system), hepatocellular balloon-
ing grade, lobular inﬂammation,
steatosis, sex, age, BMI,
T2DM, PNPLA3 genotype,
and region. aOR and 95% CI
not calculable. Abbreviations:
mITT, modiﬁed intent-to-treat;
PNPLA3, patain-like phospho-
lipase domain-containing pro-
tein 3.
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beneﬁts were observed in the larger subset of subjects
with a year 1 liver biopsy of 15 mm; improvement in
ﬁbrosis by 1 stage and no worsening of SH was
achieved by 24% (78 of 103) of CVC-treated subjects
compared to 9% (9 of 99) of placebo-treated subjects.
In this subgroup, the OR (CVC/placebo) was 3.21
(95% CI, 1.41-7.28).
A post-hoc analysis of predictors of response deter-
mined that the factors most strongly associated with
improvement in ﬁbrosis stage and no worsening of SH
at year 1 were treatment (i.e., receiving CVC), a higher
ﬁbrosis stage at baseline, mild or no portal inﬂamma-
tion at baseline, and a higher baseline BMI (P < 0.050
for each, after adjustment for the other predictors).
Although differences were observed in subgroups for
sex, region, and presence of T2DM, these factors were
not associated with response to CVC.
OTHER SECONDARY ENDPOINTS
Change in Fibrosis Stage
The shift in ﬁbrosis stage from baseline to year 1
was assessed using the NASH CRN and Ishak systems
(Supporting Fig. S3). The proportion of subjects with
a decrease in ﬁbrosis stage was 29% for CVC and 19%
for placebo using the NASH CRN system; and 35%
and 22%, respectively, using the Ishak system. A total
of 27 and 20 subjects in the CVC and placebo groups,
respectively, improved by one NASH CRN ﬁbrosis
stage (33 and 23 subjects, respectively, improved by
one Ishak ﬁbrosis stage). Eight and 3 subjects in the
CVC and placebo groups, respectively, improved by
two ﬁbrosis stages on the NASH CRN system; 10 and
4 subjects, respectively, improved by two stages on the
Ishak system. Ten subjects achieved resolution of
ﬁbrosis with CVC compared to 5 subjects on placebo
(both systems). Two subjects progressed to cirrhosis
with CVC compared to 5 subjects on placebo (both
systems).
Collagen Area by Morphometry
on Liver Biopsy
Change from baseline to year 1 in collagen area by
morphometry was analyzed as prespeciﬁed in the study
protocol. A post-hoc analysis was then performed to
evaluate the change in collagen area from baseline to
year 1, according to histological response (i.e.,
improvement in NASH CRN or Ishak stage) in sub-
jects with paired liver biopsies. At baseline, the mean
(SD) collagen area was relatively low in both groups:
2.37 (1.827) for CVC and 2.49 (2.389) for placebo.
Although mean (SD) changes from baseline to year 1
were small in both groups (0.02 [2.357] for CVC and
–0.14 [2.389] for placebo), a larger proportion of sub-
jects receiving CVC had a reduction in collagen and
improvement in ﬁbrosis by at least one stage compared
to those receiving placebo (NASH CRN: CVC 5 28
of 121 [23%], placebo 5 18 of 123 [15%]; Ishak:
CVC 5 36 of 121 [30%], placebo 5 22 of 123
[18%]). Moreover, there was good correspondence
between improvement in ﬁbrosis stage and reduction
in collagen area by morphometry; of those subjects
who achieved an improvement in ﬁbrosis stage
(whether in the CVC or placebo groups), the majority
(80% for CVC group, 75% for placebo) had a concor-
dant reduction in collagen area. When assessed simi-
larly by Ishak, 84% of CVC and 79% of placebo
subjects had a concordant improvement in both ﬁbro-
sis stage and collagen area.
Another post-hoc analysis was conducted using only
slides with liver biopsy tissue surface of 5 mm2,
where sampling variability is expected to be lower. In
subjects with collagen morphometry of 2% at base-
line, all subjects achieving at least one stage improve-
ment in ﬁbrosis (NASH CRN) had concordant
reduction in collagen at year 1. However, there was
substantial variability in changes in collagen between
baseline and year 1 in subjects with <2% collagen mor-
phometry at baseline, which represents a sizeable por-
tion of all CENTAUR subjects (Supporting Fig. S4).
Improvement in NAS
Changes in histological scores at the end of year 1
for CVC versus placebo for steatosis, lobular inﬂam-
mation, and hepatocellular ballooning are reported in
Supporting Table S4. No notable differences in the
individual components of NAS were observed.
Body weight, Liver and Fasting
Metabolic Parameters, and Noninvasive
HF Markers
There were no meaningful differences in body
weight or BMI (mean change [SD] from baseline to
year 1) between groups (–0.24 [4.177] kg for CVC
and –0.08 [4.301] for placebo for body weight; –0.13
[1.493] kg/m2 for CVC and –0.01 [1.751] kg/m2 for
placebo for BMI). Changes from baseline to year 1 in
liver transaminases, fasting metabolic parameters, and
noninvasive HF markers (NAFLD ﬁbrosis score
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TABLE 2. Change from Baseline to Year 1 in Biomarkers of Systemic Inflammation, Monocyte/Macrophage Activation,
CCR2 and CCR5 Blockade, and Hepatocellular Apoptosis (PP Population)
CVC 150 mg (N 5 144) Placebo (N 5 143)
Biomarker Baseline Year 1 Change Baseline Year 1 Change
hs-CRP
no. 110 110 110 110 110 110
Median (min, max), mg/L 2.35
(0.2, 24.0)
1.70
(0.2, 35.1)
–0.40
(–16.4, 29.1)
2.45
(0.2, 31.7)
2.55
(0.3, 34.8)
0.30
(–10.8, 28.2)
95% CI for difference in
change from baseline (CVC
150 mg—placebo)
(–1.3, –0.4)
Fibrinogen
no. 94 94 94 102 102 102
Median (min, max), mg/dL 376.5
(145, 607)
355.5
(20, 536)
–36.5
(–439, 154)
382.5
(20, 724)
392.5
(235, 760)
7.0
(–272, 569)
95% CI for difference in
change from baseline (CVC
150 mg—placebo)
(–58, –14)
IL-1b
no. 95 95 95 102 102 102
Median (min, max), pg/mL 0.090
(0.00, 2.69)
0.050
(0.00, 0.92)
–0.020
(–2.65, 0.76)
0.030
(0.00, 0.83)
0.050
(0.00, 1.05)
0.005
(–0.81, 1.02)
95% CI for difference in
change from baseline (CVC
150 mg—placebo)
(–0.06, 0)
IL-6
no. 95 95 95 102 102 102
Median (min, max), pg/mL 4.30
(1.4, 475.6)
2.60
(0.9, 521.6)
–1.50
(–13.1, 46.0)
4.50
(1.5, 22.7)
3.65
(1.0, 24.4)
–0.55
(–8.8, 12.0)
95% CI for difference in
change from baseline (CVC
150 mg—placebo)
(–1.5, –0.2)
sCD14
no. 97 97 97 103 103 103
Median (min, max), lg/L 1,731.0
(138, 3,601)
1,628.0
(768, 2,635)
–115.0
(–1,306, 1,337)
1,808.0
(1,030, 3,137)
1,803.0
(927, 3,562)
–45.0
(–1,199, 1,646)
95% CI for difference in
change from baseline (CVC
150 mg—placebo)
(–204, 19)
sCD163
no. 97 97 97 103 103 103
Median (min, max), lg/L 615.0
(263, 1,486)
615.0
(189, 1,410)
3.0
(–736, 532)
679.0
(278, 1,738)
642.0
(237, 1,927)
–41.0
(–527, 624)
95% CI for difference in
change from baseline (CVC
150 mg—placebo)
(–18, 88)
CCL2
no. 95 95 95 102 102 102
Median (min, max), pg/mL 499.00
(166.1, 1,497.4)
2,115.20
(305.9, 6,725.5)
1,674.90
(–49.8, 6,351.4)
464.50
(264.3, 763.6)
445.40
(240.3, 1,023.4)
–6.20
(–320.7, 452.3)
95% CI for difference in
change from baseline (CVC
150 mg—placebo)
(1,454, 1,878)
CCL4
no. 95 95 95 102 102 102
Median (min, max), pg/mL 90.80
(2.6, 2,432.9)
241.30
(2.5, 36,238.8)
126.00
(–227.2,
36,190.0)
92.85
(31.9, 881.0)
102.70
(5.4, 2,746.4)
5.00
(–118.0,
2,697.8)
95% CI for difference in
change from baseline (CVC
150 mg—placebo)
(103.9, 140.9)
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[NFS], FIB-4, APRI, and ELF test) were modest,
and similar between the CVC and the placebo groups
(Table 2 and Supporting Tables S5 and S6).
A post-hoc analysis was conducted to explore the
relationship between change in ﬁbrosis indices and
improvement in liver histology. Changes from baseline
to year 1 in ﬁbrosis indices were calculated for subjects
who improved in ﬁbrosis by 1 stage at year 1
(NASH CRN) and for subjects who did not
(Supporting Table S6). This post-hoc analysis was not
powered to demonstrate a difference for treatment
(CVC or placebo) and/or subgroup (histological
improvement or not). In general, more favorable
changes (i.e., smaller mean increases or larger mean
decreases) in ﬁbrosis indices (NFS, FIB-4, APRI, and
ELF) were observed in subjects in whom ﬁbrosis
improved by 1 stage at year 1 relative to subjects in
whom ﬁbrosis did not improve. These observations
were noted in subjects who received CVC and in those
who received placebo.
Biomarkers of Inﬂammation
Marked reductions in circulating biomarkers of sys-
temic inﬂammation (high-sensitivity C-reactive pro-
tein [hs-CRP], interleukin [IL]-6, ﬁbrinogen, and IL-
1ß) and of monocyte activation (sCD14) were
observed with CVC (vs. placebo; Table 2). Reciprocal
increases in chemokine (C-C motif) ligands (CCL) 2
and 4 were observed in CVC-treated subjects only,
conﬁrming potent CCR2 and CCR5 blockade, as pre-
viously described.(16,17,22)
A post-hoc analysis was conducted to evaluate corre-
lations between change in markers of inﬂammation,
where pronounced treatment differences were observed
(i.e., hs-CRP, IL-6, ﬁbrinogen, IL-1ß, and sCD14),
and change in markers of insulin sensitivity (i.e.,
hemoglobin A1c [HbA1c], homeostatic model of
assessment of insulin resistance, and adipose tissue
insulin resistance). The results showed limited, if any,
relationship (Spearman’s rank correlation of 0.20 or
less for almost all comparisons; data not shown).
SAFETY AND TOLERABILITY
The safety population comprised all 288 subjects
who were randomized and received at least one dose of
study drug. The incidence of treatment-emergent
adverse events was similar in both groups, and in gen-
eral mild or moderate in severity (Supporting Table
S7).
Twenty-six treatment-emergent serious adverse
events were reported (CVC, n 5 16; placebo, n 5 10).
All serious adverse events but one (grade 2 arrhyth-
mia; subject remained on blinded treatment) were
considered not related to treatment. The incidence of
treatment-emergent grade 3 or 4 laboratory abnor-
malities was generally similar between groups. Grade
4 uric acid elevations, which occurred in subjects
with increased baseline values, and asymptomatic
grade 3 amylase elevations were observed more fre-
quently in the CVC than placebo group (7.6% vs.
4.2% and 4.2% vs. 0.7%, respectively; Supporting
Table S7). No treatment-emergent adverse events of
TABLE 2. Continued
CVC 150 mg (N 5 144) Placebo (N 5 143)
Biomarker Baseline Year 1 Change Baseline Year 1 Change
CK-18 (caspase-cleaved [M30])
no. 97 97 97 103 103 103
Median (min, max) 624.0
(125, 2,353)
433.0
(107, 2,562)
–77.0
(–1,600, 1,365)
704.0
(98, 3,564)
472.0
(37, 2,426)
–155.0
(–2,240, 1,368)
95% CI for difference in
change from baseline (CVC
150 mg—placebo)
(–25, 228)
CK-18 (total [M65])
no. 97 97 97 103 103 103
Median (min, max) 421.0
(104, 3,673)
438.0
(84, 7,031)
1.0
(–1,273, 6,296)
448.0
(113, 2,149)
415.0
(100, 6,023)
–22.0
(–1,156, 5,119)
95% CI for difference in
change from baseline (CVC
150 mg – placebo)
(–45, 151)
Abbreviations: CK-18, cytokeratin 18; PP, per protocol.
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pancreatitis were reported in subjects with grade 3
amylase elevations.
Changes from baseline in liver biochemistry and
fasting metabolic parameters are reported in Support-
ing Table S5.
Discussion
NASH is highly prevalent globally and represents
an unmet medical need, based on related morbidity
and mortality burdens, and the lack of approved thera-
pies.(1) CENTAUR prospectively analyzed and
reported on composite clinical efﬁcacy endpoints cur-
rently being evaluated in phase 3 NASH studies
(NCT02548351, NCT02704403, and NCT030287
40; https://clinicaltrials.gov), and demonstrated a ben-
eﬁt on ﬁbrosis in subjects with NASH after only 1 year
of treatment. Although the primary outcome was not
met, twice as many subjects on CVC than placebo
achieved the clinically important key secondary out-
come of improvement in ﬁbrosis by 1 stage and no
worsening of SH. Fibrosis is the only histological fea-
ture that has been independently associated with clini-
cal outcomes in longitudinal cohorts.(3-5) CENTAUR
exclusively enrolled subjects with NASH and LF;
additionally, subjects were required to have active met-
abolic dysfunction (T2DM or MetS), a well-known
risk factor for disease progression. The primary out-
come was chosen based on the standard established in
past phase 2 studies that assessed the efﬁcacy of
NASH therapies.(9,10) Improvement in ﬁbrosis by 1
stage and no worsening of SH was selected as one of
the two key secondary outcomes, both because of its
association with clinical outcomes and to inform the
phase 3 program. Greater CVC treatment beneﬁts
were observed in subjects with higher disease activity
and ﬁbrosis stage (i.e., NAS 5, prominent hepatocel-
lular ballooning, and moderate-to-severe ﬁbrosis);
these observations help identify which patients are
most likely to beneﬁt from CVC treatment and are
aligned with known risk factors of disease progression.
The majority of subjects who achieved an improve-
ment in ﬁbrosis stage also achieved a reduction in col-
lagen area by morphometry, supporting ﬁndings from
secondary efﬁcacy endpoints related to improvement in
ﬁbrosis.
The safety and tolerability of NASH therapies are
paramount, because the condition is typically asymp-
tomatic and patients are often being treated for comor-
bidities including T2DM and CVD. In CENTAUR,
the incidence of treatment-emergent adverse events
and laboratory abnormalities was comparable between
CVC and placebo. The most frequently reported
treatment-emergent adverse events of at least moderate
severity (i.e., fatigue, diarrhea, and headache) were
consistent with the extensive clinical experience with
CVC in past studies.(16,17,22) Changes in fasting meta-
bolic parameters from baseline were relatively small
and comparable between groups, indicating that CVC
is not likely to worsen pre-existing metabolic disease in
NASH patients.
The results of CENTAUR are potentially
paradigm-shifting, given that they challenge the com-
mon assumption that the antiﬁbrotic effects of NASH
agents can only be observed by improving the underly-
ing metabolic liver disease. Instead, the beneﬁcial
impact of CVC on ﬁbrosis without affecting the histo-
logical features of SH at year 1 reinforces the rationale
for directly targeting inﬂammatory and ﬁbrotic mecha-
nisms. The antiﬁbrotic activity of CVC observed here
is consistent with ﬁndings in several animal models of
chronic liver injury.(11) Although the study did not
meet the primary endpoint at year 1, it nonetheless
underscores the evolving principles of clinical-trial
design that increasingly look to assign endpoints that
are aligned with the mechanism of action.
Based on its mechanism of action, the lack of effect
of CVC on lobular inﬂammation was unexpected and
will need to be further explored. One possible expla-
nation may be that the impact of CVC on the com-
position of immune cells in the inﬂamed lobule, as
well as the noncellular components of inﬂammation
(i.e., chemokines and soluble mediators), cannot be
fully characterized by the hematoxylin-eosin stain
alone (used to grade the degree of lobular inﬂamma-
tion). Detailed characterization of immune cell subsets
will be valuable in the future to further clarify the
impact of CVC on hepatic inﬂammation. Although
the NAS has been widely used to evaluate early treat-
ment effects in phase 2 studies, it does not distinguish
targeted effects of CVC on CCR2-expressing mono-
cyte-derived macrophages, as demonstrated in models
of liver injury.(12,14) Speciﬁcally, activities of chemo-
kine signaling, including intrahepatic monocyte and
macrophage recruitment and ﬁbrogenesis, occur
downstream of liver-cell injury and metabolic dysre-
gulation in the pathophysiology of NASH; therefore,
they may not be reﬂected in the traditional histologi-
cal features of the NAS, including steatosis, lobular
inﬂammation, and hepatocellular ballooning. There-
fore, further evaluation using cell-speciﬁc markers will
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be required to elucidate the effects of CVC on
immune cells in patients.
Importantly, a broad mechanistic impact of CVC
on inﬂammatory signaling is underscored by reduc-
tions in circulating markers of systemic inﬂammation
(ie, hs-CRP, IL-6, ﬁbrinogen) and sCD14 (a marker
of monocyte activation), which is consistent with pre-
vious studies in subjects with HIV infection.(17,22)
In this study in subjects with NASH, a large histo-
logical data set of 252 paired biopsies was available for
year 1 evaluation in the modiﬁed ITT population. All
liver biopsies were read centrally by a single patholo-
gist, thereby reducing reader variability. Limitations of
our study include: differences in responses among sub-
groups (e.g., region, sex, and T2DM) that may reﬂect
the multifactorial nature of the disease or be associated
with the sample size of the subgroups; and the inherent
variability of liver biopsy sampling,(23) which will
require further investigation in subsequent studies.
Improvement in ﬁbrosis stage has been reported in
phase 2 NASH randomized clinical trials, in some
studies as early as 24 weeks.(10,24,25) These and similar
studies have also demonstrated that a small, but signiﬁ-
cant, proportion of subjects, up to approximately
20%,(8-10) will have spontaneous improvement on pla-
cebo. This improvement has often been attributed to
increased clinical monitoring, motivation, and compli-
ance to diet and lifestyle changes of subjects participat-
ing in such trials. Therefore, the observation that some
placebo subjects improved in the CENTAUR study is
neither unexpected nor out of line with other reported
results.
In conclusion, CVC showed a signiﬁcant antiﬁ-
brotic beneﬁt at year 1 and was well tolerated.
Although the primary endpoint of the study was not
met, the fact that the CENTAUR year 1 study results
showed that CVC provided clinically meaningful ben-
eﬁts and resulted in twice as many subjects achieving
“improvement in ﬁbrosis by 1 stage and no worsen-
ing of SH” as compared to placebo suggests that the
study did, in fact, show proof of concept, warranting
phase 3 development of CVC. If this beneﬁt is corrob-
orated by the continued follow-up over the planned
second year of treatment, and subsequent conﬁrmatory
trials, CVC will represent an important advance in the
treatment of LF in patients with NASH.
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